Immutep Investor Relations Material
Latest events
AGM 2024
Immutep
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immutep Limited
Access all reports
Immutep Limited is a clinical-stage biotechnology company, recognized for its pioneering work in developing novel immunotherapy for cancer and autoimmune diseases. The company's research and development efforts are centered on Lymphocyte Activation Gene-3 (LAG-3), a crucial cell surface molecule that plays a significant role in regulating the immune system. Immutep's portfolio includes a range of innovative immunotherapies designed to either stimulate or suppress the immune system to combat cancer or autoimmune diseases. The company is headquartered in Sydney, Australia, and its shares are listed on the Nasdaq.
Key slides for Immutep Limited
AGM 2024
Immutep Limited
Study Result Presentation
Immutep Limited
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IMM
Country
🇦🇺 Australia